CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 1,310.4	$ 597.3
Trade receivables, net	2,692.7	2,686.9
Inventories, net	1,320.2	1,256.6
Prepaid expenses and other current assets	910.4	966.4
Total current assets	6,233.7	5,507.2
Property, plant and equipment, net	1,465.5	1,441.8
Intangible assets, net	22,346.0	23,083.0
Goodwill	18,600.7	18,552.8
Deferred tax assets, net	163.2	156.0
Other long-term assets, net	210.8	223.7
Total assets	49,019.9	48,964.5
Current liabilities:
Accounts payable	438.1	433.7
Accrued and other current liabilities	3,337.9	3,859.1
Acquisition-related contingent consideration	146.3	196.8
Current portion of long-term debt	675.1	823.0
Total current liabilities	4,597.4	5,312.6
Acquisition-related contingent consideration	951.7	959.1
Long-term debt	31,303.4	30,265.4
Pension and other benefit liabilities	194.8	190.4
Liabilities for uncertain tax positions	117.7	120.2
Deferred tax liabilities, net	5,896.6	5,902.4
Other long-term liabilities	182.7	184.6
Total liabilities	$ 43,244.3	$ 42,934.7
Commitments and contingencies
Equity
Common shares	$ 9,905.9	$ 9,897.4
Additional paid-in capital	351.6	304.9
Accumulated deficit	(3,123.4)	(2,749.7)
Accumulated other comprehensive loss	(1,478.6)	(1,541.6)
Total Valeant Pharmaceuticals International, Inc. shareholders’ equity	5,655.5	5,911.0
Noncontrolling interest	120.1	118.8
Total equity	5,775.6	6,029.8
Total liabilities and equity	$ 49,019.9	$ 48,964.5